International treaty obligations: TRIPS and generic access

Imagine a situation where saving lives depends on signing a complex legal paper. That is exactly what happens when governments try to secure affordable medicines. You might think patent laws protect innovation, but for many people around the world, they often mean waiting longer for cures or paying prices they cannot afford. This conflict sits at the heart of the World Trade Organization’s agreement on intellectual property.

The core issue is straightforward. Rich countries demand protection for their drug companies to make money. Poorer nations need those same drugs for their sick citizens immediately. When these two goals clash, the result is usually expensive treatments locked behind legal barriers. Understanding how international treaties shape this balance helps us see why some patients get help while others do not.

What is the TRIPS Agreement? Defined

To understand the barrier, we must look at the rulebook itself. The Agreement on Trade-Related Aspects of Intellectual Property Rights is an international treaty. Commonly known as the TRIPS Agreement, it sets minimum standards for how countries protect intellectual property. TRIPS This agreement came into force on January 1, 1995, managed by the World Trade Organization(WTO). Before this date, nations could decide their own rules for patents. Some allowed local factories to copy drugs freely; others did not.

TRIPS changed that. It required every member country to provide patent protection for pharmaceutical products for 20 years. This standardization was meant to encourage invention. However, it also stopped countries like India from producing cheap versions of patented drugs. Previously, Indian manufacturers could sell medicines for roughly 5% to 10% of the price set by patent holders. Under TRIPS, that freedom vanished overnight for new inventions.

The Impact on Medicine Prices

When a patent lasts 20 years, the company owns the right to sell that specific drug alone. They set the price, often very high to recoup research costs. In wealthy markets like the United States, insurance companies pay these costs. In low-income regions, governments and families pay out of pocket. The difference is stark.

Generic Medicinesare copies of brand-name drugs produced after the original patent expires. Without these generics, treatment can cost tens of thousands of dollars per year. With them, the price drops significantly. For example, HIV medication in South Africa dropped from $10,000 per patient annually to about $87 thanks to the threat of competition and pressure from public health groups. This shows how powerful the market becomes once the monopoly ends.

• Patented Drugs: Limited supply, high prices, controlled by one manufacturer.
• Generic Drugs: Multiple suppliers, competitive prices, open market.
• Impact: A shift from generics to patents raised global medicine spending by billions.

This dynamic creates a crisis in healthcare. If a country follows TRIPS strictly, its citizens wait until patents expire for affordable care. Many die during that wait time. The legal framework thus acts as a gatekeeper to survival.

Flexibilities within the Law

By the early 2000s, the AIDS pandemic was raging. Governments realized strict TRIPS rules were killing people. They pushed back. In 2001, members adopted the Doha Declaration on the TRIPS Agreement and Public HealthA legal interpretation allowing countries to prioritize public health over patent rights during emergencies..

This declaration gave nations "flexibilities." These are escape routes built into the treaty. They allow a government to ignore a patent under specific conditions. The most important tool here is Compulsory LicensingA legal permission granted by a government authorizing the production of a patented product without the owner's consent..

A government can declare a national emergency-like an epidemic-and order a local factory to make a copy of the drug. They still have to pay the original company, but the fee is much lower than normal royalties. This mechanism acknowledges that health is a right, even when patents are a privilege.

The Rwanda-Canada Experiment

There is a special case in the rules called the Article 31bis amendment. This fixed a loophole. If a country has no factory making medicine, it couldn't issue a license. The amendment allowed a country without manufacturing capacity to import generic drugs from another country. It sounds perfect in theory. In practice, it is slow.

In 2008, Rwanda became the first nation to use this system. It ordered HIV medicine from Canada through Apotex Corporation. The process took four years. By the time the deal closed, both sides agreed the paperwork was too heavy. Médecins Sans Frontières noted the system was unworkable. The bureaucracy involved notifying the WTO weeks in advance and satisfying export permits slowed everything down.

Rwanda paid for generic HIV drugs worth $1.3 million. While cheaper than the branded version, it was still 30% more expensive than if Rwanda had its own factory to make them. This single case highlights the difficulty of relying on foreign production when you lack domestic capacity.

Why Countries Hesitate to Act

You might wonder why nations do not use these flexibilities more often. A study from Duke University found that 92% of low- and middle-income countries lack dedicated staff to manage these procedures. It takes a team of lawyers and scientists to draft a valid compulsory license. Most ministries of health do not have that budget.

There is also the threat of political pressure. Wealthy nations sometimes warn developing countries not to issue licenses. In 2009, the U.S. placed Thailand on its Priority Watch List after Thailand licensed generic clopidogrel and imatinib. Thailand lost its special trade benefits, costing an estimated $57 million in exports. This kind of punishment makes governments think twice before using their legal rights.

Furthermore, Trade AgreementsBilateral deals that add stricter IP rules beyond international norms. often impose "TRIPS-plus" standards. These agreements require longer patent terms, sometimes extending beyond the 20-year limit. As of 2023, 58 LMICs were negotiating such deals, locking them into stricter rules than the WTO requires.

The Push for Reform

Despite these hurdles, activists and governments keep pushing. During the COVID-19 pandemic, India and South Africa proposed waiving IP rights for vaccines entirely. The WTO approved a partial waiver in June 2022. It covered vaccines but excluded medicines and tests, which limited its effect.

Recent meetings in 2024 urged reforms to prevent future pandemics. The consensus suggests that current rules are too rigid for global health crises. Organizations like the Medicines Patent Pool offer an alternative. Companies voluntarily license patents to manufacturers, creating a pool of technology available for generic production. While helpful, it covers only a small fraction of necessary drugs.

We are now seeing a shift toward local production rather than imports. Digital health strategies now reference these flexibilities to boost local tech manufacturing. The goal remains the same: ensuring that the law serves life, not just profit margins.

Frequently Asked Questions

The relationship between international trade law and basic human health remains tense. As negotiations continue in 2026, the question is whether the legal frameworks will evolve to prioritize accessibility. Until then, millions continue to wait behind patent walls.